Could a Sugar-Blocking drug help cystic fibrosis lungs?
NCT ID NCT02325362
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether miglustat, a drug that blocks certain sugar processing, can improve salt movement in the noses of adults with cystic fibrosis who have the F508del gene mutation. Sixteen participants took miglustat for two weeks and a placebo for two weeks, with a washout period in between. The goal was to see if miglustat could restore function of the faulty CFTR protein.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
miglustat
What this could lead to
If it works, this could point toward a treatment that helps cystic fibrosis patients with the F508del mutation breathe easier.
What could go wrong
This is a very small, early study with only 16 people. It may not show clear benefit, and miglustat can cause side effects like diarrhea or tremors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance publique-Hôpitaux de Paris, Hôpital Cochin
Paris, 75014, France